Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 5/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.43 |
| ▸ | PDE1A | P54750 | 7/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 7/20 | 0.43 |
| ▸ | PDE2A | O00408 | 6/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454858 | 0.93 | PDE1A (0.48) | USP1PDE1BPDE1APDE1CPDE2A | |
| SCHEMBL13334343 | 0.88 | PDE1B (0.42) | USP1PDE1BPDE1APDE1CPDE2A | |
| SCHEMBL2458078 | 0.84 | PDE1B (0.45) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL2454975 | 0.82 | PDE1B (0.51) | PDE1BPDE1APDE1CPDE2ATP53 | |
| SCHEMBL9608337 | 0.81 | PDE1B (0.48) | PDE1BPDE1APDE1CPDE2ATP53 | |
| SCHEMBL2535845 | 0.81 | PDE1B (0.49) | PDE1BPDE1APDE1CPDE2ATP53 | |
| SCHEMBL9608320 | 0.80 | PDE2A (0.39) | USP1PDE1BPDE2ACHRM1PDE4D | |
| SCHEMBL9608334 | 0.79 | PDE1B (0.52) | PDE1BPDE1APDE1CPDE2ATP53 | |
| SCHEMBL2454720 | 0.79 | PDE1B (0.50) | PDE1BPDE1APDE1CPDE2ATP53 | |
| SCHEMBL9608328 | 0.79 | CHRM1 (0.42) | USP1PDE1BPDE1APDE1CCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353556-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-12-10 | — | — | US | disclosed |
| US-8927556-B2 | 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120136013-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES. INC. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353556-A1 | ORGANIC COMPOUNDS | CYP2C9, TPMT, CYP2C19 | USP1 4631/4885PDE1B 4863/4885PDE1A 4874/4885 |
| US-20120136013-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | USP1 4645/4885PDE1B 4855/4885PDE1A 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.